| __timestamp | Dyne Therapeutics, Inc. | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 1145000000 | 17345000000 |
| Thursday, January 1, 2015 | 2028000000 | 17404000000 |
| Friday, January 1, 2016 | 2281000000 | 17520000000 |
| Sunday, January 1, 2017 | 2932000000 | 17175000000 |
| Monday, January 1, 2018 | 24000 | 18407000000 |
| Tuesday, January 1, 2019 | 271000 | 14425000000 |
| Wednesday, January 1, 2020 | 700000 | 15121000000 |
| Friday, January 1, 2021 | 1088000 | 15867000000 |
| Saturday, January 1, 2022 | 3345000 | 15486000000 |
| Sunday, January 1, 2023 | 2461000 | 12472000000 |
| Monday, January 1, 2024 | 12827000000 |
Infusing magic into the data realm
In the ever-evolving landscape of the pharmaceutical industry, understanding cost efficiency is crucial. This analysis compares the cost of revenue efficiency between Novartis AG, a global healthcare giant, and Dyne Therapeutics, Inc., a burgeoning biotech firm, from 2014 to 2023. Novartis AG consistently maintained a high cost of revenue, peaking at approximately $18.4 billion in 2018, reflecting its expansive operations and market reach. In contrast, Dyne Therapeutics, Inc. exhibited significant fluctuations, with a notable dip in 2018, where costs plummeted to just $24,000. This stark contrast highlights the differing scales and operational strategies of these companies. Over the decade, Novartis AG's cost of revenue decreased by about 28%, while Dyne Therapeutics, Inc. saw a dramatic 99% reduction in 2018, followed by a gradual increase. This data underscores the dynamic nature of cost management in the pharmaceutical sector.
Cost of Revenue: Key Insights for Merck & Co., Inc. and Dyne Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Novartis AG vs Vertex Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Novartis AG vs Corcept Therapeutics Incorporated
Cost of Revenue Comparison: Novartis AG vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Trends: Novartis AG vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: Novartis AG vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Viatris Inc. vs Dyne Therapeutics, Inc.
Cost of Revenue: Key Insights for Dr. Reddy's Laboratories Limited and Dyne Therapeutics, Inc.
Cost of Revenue: Key Insights for HUTCHMED (China) Limited and Dyne Therapeutics, Inc.
Analyzing Cost of Revenue: Ligand Pharmaceuticals Incorporated and Dyne Therapeutics, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Dyne Therapeutics, Inc.'s Expenses
Dyne Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored